Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia.
Puła B, Pruszczyk K, Pietrusza E, Morawska M, Piszczek W, Kalicińska E, Szeremet A, Tryc-Szponder J, Wąsik-Szczepanek E, Drozd-Sokołowska J, Krzemień H, Rejus A, Gajewska M, Wiśniewski K, Wysocki M, Majeranowski A, Paszkiewicz-Kozik E, Steckiewicz P, Szukalski Ł, Bołkun Ł, Długosz-Danecka M, Giannopoulos K, Jamroziak K, Lech-Marańda E, Hus I. Puła B, et al. Cancers (Basel). 2022 Jan 22;14(3):558. doi: 10.3390/cancers14030558. Cancers (Basel). 2022. PMID: 35158826 Free PMC article.
Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia.
Robak T, Blonski JZ, Gora-Tybor J, Calbecka M, Dwilewicz-Trojaczek J, Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J, Stella-Holowiecka B, Sulek K, Kuliczkowski K, Potoczek S, Warzocha K, Lech-Maranda E, Skotnicki AB, Piotrowska M, Moskwa A, Zawilska K, Jamroziak K. Robak T, et al. Leuk Lymphoma. 2014 Mar;55(3):606-10. doi: 10.3109/10428194.2013.809073. Epub 2013 Nov 14. Leuk Lymphoma. 2014. PMID: 23721512 Clinical Trial.
Bendamustine as monotherapy and in combination regimens for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma: a retrospective analysis.
Hus I, Jawniak D, Gorska-Kosicka M, Butrym A, Dzietczenia J, Wrobel T, Grzegorz M, Lech-Maranda E, Warzocha K, Waszczuk-Gajda A, Jedrzejczak WW, Krawczyk-Kulis M, Kyrcz-Krzemien S, Poplawska L, Walewski J, Dmoszynska A. Hus I, et al. Chemotherapy. 2013;59(4):280-9. doi: 10.1159/000357468. Epub 2014 Jan 21. Chemotherapy. 2013. PMID: 24457828
Real‑life experience with bortezomib‑based regimens in elderly patients with newly diagnosed multiple myeloma and comorbidities: a Polish retrospective multicenter study.
Hus I, Walter-Croneck A, Masternak A, Jurczyszyn A, Usnarska-Zubkiewicz L, Bołkun Ł, Druzd-Sitek A, Rymko M, Łętowska J, Lech-Marańda E, Pasiarski M, Dmoszyńska A. Hus I, et al. Pol Arch Intern Med. 2017 Nov 30;127(11):765-774. doi: 10.20452/pamw.4099. Epub 2017 Sep 14. Pol Arch Intern Med. 2017. PMID: 28906482 Free article.
Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
Białopiotrowicz E, Górniak P, Noyszewska-Kania M, Puła B, Makuch-Łasica H, Nowak G, Bluszcz A, Szydłowski M, Jabłonska E, Piechna K, Sewastianik T, Polak A, Lech-Marańda E, Budziszewska BK, Wasylecka-Juszczyńska M, Borg K, Warzocha K, Czardybon W, Gałęzowski M, Windak R, Brzózka K, Juszczyński P. Białopiotrowicz E, et al. J Cell Mol Med. 2018 Jul;22(7):3548-3559. doi: 10.1111/jcmm.13632. Epub 2018 Apr 17. J Cell Mol Med. 2018. PMID: 29665227 Free PMC article.
Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
Puła B, Budziszewska BK, Rybka J, Gil L, Subocz E, Długosz-Danecka M, Zawirska D, Waszczuk-Gajda A, Iskierka-Jażdżewska E, Kopacz A, Szymczyk A, Czyż J, Lech-Marańda E, Warzocha K, Jamroziak K. Puła B, et al. Anticancer Res. 2018 May;38(5):3025-3030. doi: 10.21873/anticanres.12557. Anticancer Res. 2018. PMID: 29715135
The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
Charlinski G, Grzasko N, Jurczyszyn A, Janczarski M, Szeremet A, Waszczuk-Gajda A, Bernatowicz P, Swiderska A, Guzicka-Kazimierczak R, Lech-Maranda E, Szczepaniak A, Wichary R, Dmoszynska A. Charlinski G, et al. Eur J Haematol. 2018 Sep;101(3):354-361. doi: 10.1111/ejh.13106. Epub 2018 Jul 12. Eur J Haematol. 2018. PMID: 29882602
120 results